Low-Dose Oral Sirolimus and the Risk of Menstrual-Cycle Disturbances and Ovarian Cysts: Analysis of the Randomized Controlled SUISSE ADPKD Trial

Sirolimus has been approved for clinical use in non proliferative and proliferative disorders. It inhibits the mammalian target of rapamycin (mTOR) signaling pathway which is also known to regulate ovarian morphology and function. Preliminary observational data suggest the potential for ovarian toxi...

Descripción completa

Detalles Bibliográficos
Autores principales: Braun, Matthias, Young, James, Reiner, Cäcilia S., Poster, Diane, Krauer, Fabienne, Kistler, Andreas D., Kristanto, Paulus, Wang, Xueqi, Liu, Yang, Loffing, Johannes, Andreisek, Gustav, von Eckardstein, Arnold, Senn, Oliver, Wüthrich, Rudolf P., Serra, Andreas L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2012
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3468602/
https://www.ncbi.nlm.nih.gov/pubmed/23071528
http://dx.doi.org/10.1371/journal.pone.0045868

Ejemplares similares

Ejemplares similares